Safinamide, MAO-B inhibitor, Parkinson’s therapeutic (TBI2924)

Description

Product Details

Formal Name: (S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propenamide

Alternate Names: FCE-26743; PNU-151774E; NW-1015

Molecular Formula: C₁₇H₁₉F₂N₄O₂

Formula Weight: 302.3

CAS Number: 133865-89-1

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 50 mg/ml)

Storage: -20°C

Stability: ≥ 2 years.

 

Applications

MAO-B inhibitor, Parkinson’s therapeutic

 

Functions

A selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A. Displays anticonvulsant activity and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models. Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade. A novel therapeutic for Parkinson’s disease with multiple modes of action. Effective as an add-on to dopamine agonist therapy in early Parkinson’s.

 

Application Procedures

First dissolved in DMSO (up to 50 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 2 months.

Additional information

SIZE (mg)	25 MG, 5 MG

Datasheet:

TBI2924_Safinamide

MSDS:

TBI2924_Safinamide_MSDS_2024